Author
Listed:
- Yung-En Tsai
(Department of Ophthalmology, Kaohsiung Armed Forces General Hospital, Kaohsiung 802, Taiwan
Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)
- Yi-Hao Chen
(Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)
- Chien-An Sun
(Department of Public Health, College of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan
Big Data Research Center, College of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan)
- Chi-Hsiang Chung
(Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
School of Public Health, National Defense Medical Center, Taipei 114, Taiwan
Taiwanese Injury Prevention and Safety Promotion Association, Taipei 114, Taiwan)
- Wu-Chien Chien
(Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
School of Public Health, National Defense Medical Center, Taipei 114, Taiwan
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan)
- Ke-Hung Chien
(Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan)
Abstract
Background: This study aimed to investigate the associated risk between using fibrate and open-angle glaucoma (OAG) in hyperlipidemic patients from the National Health Insurance Research Database (NHIRD). Methods: We collected data over a 16-year period from the NHIRD, and used the Fisher’s exact test and Pearson chi-square test to analyze variables. Adjusted hazard ratios (aHR) were used to examine the risk factors for disease development. We applied Kaplan–Meier analysis to compare the cumulative incidence of OAG. Results: A total of 10,011 patients using fibrate were enrolled in the study cohort, and 40,044 patients not using fibrate were enrolled in the control cohort. The incidence of OAG was lower in the study cohort than in the control cohort (aHR = 0.624, p = 0.007). The overall incidence of OAG was 463.02 per 100,000 person-years in the study cohort and 573.65 per 100,000 person-years in the control cohort. We used the Kaplan–Meier method to calculate the cumulative risk of developing OAG. The results revealed that after using fibrate for over seven years, the study cohort had a greatly lower rate of developing OAG than the control cohort (log-rank test p = 0.050). Conclusions: Our studies showed that using fibrate for over seven years may lead to a lower risk of OAG in patients with hyperlipidemia. Nevertheless, further prospective studies that comprehensively investigate the relationship between using fibrate and OAG are needed.
Suggested Citation
Yung-En Tsai & Yi-Hao Chen & Chien-An Sun & Chi-Hsiang Chung & Wu-Chien Chien & Ke-Hung Chien, 2022.
"Relationship between Using Fibrate and Open-Angle Glaucoma in Hyperlipidemic Patients: A Population-Based Cohort Study,"
IJERPH, MDPI, vol. 19(4), pages 1-9, February.
Handle:
RePEc:gam:jijerp:v:19:y:2022:i:4:p:2415-:d:753498
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:4:p:2415-:d:753498. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.